In addition, the up-regulation of miR-351 protected against insulin resistance and liver gluconeogenesis by repressing the PI3K/AKT pathway and regulating flotillin 2 in GDM mice; this highlights miR-351 as a potential therapeutic target for the clinical management of GDM (77). This evidence concerns the gene FLOT2 and gestational diabetes.